Aeglea Bio Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AGLE Nasdaq 8731 https://www.aeglea.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aeglea Bio Therapeutics Inc

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency - Jan 6th, 2023 12:01 pm
Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely - Jan 2nd, 2023 12:29 pm
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade - Dec 14th, 2022 5:00 pm
Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 2nd, 2022 9:05 pm
Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease - Nov 30th, 2022 3:38 pm
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer - Nov 30th, 2022 12:01 pm
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer - Nov 15th, 2022 9:25 pm
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates - Nov 3rd, 2022 12:35 pm
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates - Nov 3rd, 2022 11:01 am
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers - Oct 21st, 2022 4:27 pm
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition - Oct 21st, 2022 4:06 pm
Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment - Oct 19th, 2022 8:05 pm
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce - Oct 17th, 2022 3:57 pm
FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients - Oct 4th, 2022 3:05 pm
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program - Oct 4th, 2022 11:01 am
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 - Aug 29th, 2022 8:05 pm
Trade Alert: Marcio De'Souza At Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), Has Just Spent US$50k Buying A Small Number of Shares - Aug 27th, 2022 1:18 pm
Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down - Aug 25th, 2022 3:52 pm
Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus - Aug 24th, 2022 4:40 pm
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring - Aug 24th, 2022 12:01 pm